

***Fiscal Year 2017 Autism Research Program
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadlines |
|--|--|--|---|---|
| <p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-17-ARP-CTA</p> | <p>Investigators at or above the level of Associate Professor (or equivalent) or</p> <p>Early-Career Investigator Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with an Early-Career Investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Must be within the first year of postdoctoral fellowship by the application deadline • Is no more than 7 years from the receipt of a terminal degree • Has the freedom to commit at least 50% time to the project | <ul style="list-style-type: none"> • Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD). • Applications in the following areas are strongly encouraged: <ul style="list-style-type: none"> ○ Behavioral, cognitive, and other non-pharmacological therapies. Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged. ○ Pharmacological treatments in ASD. Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged. ○ Dissemination/implementation of clinically validated interventions across the lifespan. ○ Therapies to alleviate conditions co-occurring with ASD. ○ Interventions promoting success in key transitions to adulthood for individuals living with ASD. ○ Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD, particularly adulthood. • Preliminary data relevant to the proposed project are required. • Pre-application is required; application submission is by invitation only. • Nested Early-Career Investigator Option supports the development of young investigators pursuing or wishing to pursue clinical trials. | <ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$1,000,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. <p>Nested Early-Career Investigator Option:</p> <ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$1,300,000 for direct costs (plus indirect costs). | <p>Pre-Application: July 26, 2017 5:00 p.m. Eastern time (ET)</p> <p>Invitation to Submit an Application: September 1, 2017</p> <p>Application: October 19, 2017 11:59 p.m. ET</p> |

***Fiscal Year 2017 Autism Research Program
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadlines |
|--|---|---|---|--|
| <p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-17-ARP-IDA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent)</p> | <ul style="list-style-type: none"> • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes. • Applications in the following areas are strongly encouraged: <ul style="list-style-type: none"> ○ Assessment of novel therapeutics using valid preclinical models. ○ Environmental risk factors. ○ Mechanisms of heterogeneous clinical expression of ASD. ○ Mechanisms underlying conditions co-occurring with ASD. ○ Factors promoting success in key transitions to independence for individuals living with ASD. ○ Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD, particularly in adulthood. ○ Cultural factors in treatment efficacy, delivery, and access to services. • Preliminary data are required. • Pre-application is required; application submission is by invitation only. • Multiple Principal Investigator (PI) Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award. | <ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$500,000 in direct costs. • For multiple PIs, the combined funding for all PIs for the entire period of performance may not exceed \$500,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. | <p>Pre-Application: July 26, 2017 5:00 p.m. ET</p> <p>Invitation to Submit an Application: September 1, 2017</p> <p>Application: October 19, 2017 11:59 p.m. ET</p> |

***Fiscal Year 2017 Autism Research Program
Reference Table of Award Mechanisms and Submission Requirements***

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadlines |
|--|---|--|---|---|
| <p>Clinical Translational Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-17-ARP-CTRA</p> | <p>Investigators at or above the level of Assistant Professor (or equivalent)</p> | <ul style="list-style-type: none"> • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD. • Applications in the following areas are strongly encouraged: <ul style="list-style-type: none"> ○ Behavioral, cognitive, and other non-pharmacological therapies. Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged. ○ Pharmacological treatments in ASD. Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged. ○ Dissemination/implementation of clinically validated interventions across the lifespan. ○ Therapies to alleviate conditions co-occurring with ASD. ○ Interventions promoting success in key transitions to adulthood for individuals living with ASD. ○ Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD, particularly in adulthood. • Preliminary data relevant to the proposed project are required. • Pre-application is required; application submission is by invitation only. | <ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$500,000 in direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. | <p>Pre-Application: July 26, 2017 5:00 p.m. Eastern time (ET)</p> <p>Invitation to Submit an Application: September 1, 2017</p> <p>Application: October 19, 2017 11:59 p.m. ET</p> |